Nuvalent Inc has a consensus price target of $87.55 based on the ratings of 12 analysts. The high is $115 issued by Stifel on July 10, 2024. The low is $40 issued by Piper Sandler on August 23, 2021. The 3 most-recent analyst ratings were released by Stifel, Wedbush, and Jefferies on July 10, 2024, May 17, 2024, and April 17, 2024, respectively. With an average price target of $103.67 between Stifel, Wedbush, and Jefferies, there's an implied 25.64% upside for Nuvalent Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/10/2024 | Buy Now | 39.38% | Stifel | Bradley Canino | $103 → $115 | Maintains | Buy | Get Alert |
05/17/2024 | Buy Now | 19.99% | Wedbush | David Nierengarten | → $99 | Reiterates | Outperform → Outperform | Get Alert |
04/17/2024 | Buy Now | 17.56% | Jefferies | Roger Song | → $97 | Initiates | → Buy | Get Alert |
04/01/2024 | Buy Now | 33.32% | Leerink Partners | Andrew Berens | $69 → $110 | Upgrade | Market Perform → Outperform | Get Alert |
03/06/2024 | Buy Now | 18.77% | JP Morgan | Anupam Rama | $68 → $98 | Maintains | Overweight | Get Alert |
02/28/2024 | Buy Now | 19.99% | Guggenheim | Kelsey Goodwin | → $99 | Assumes | → Buy | Get Alert |
02/28/2024 | Buy Now | 23.62% | BMO Capital | Etzer Darout | $93 → $102 | Maintains | Outperform | Get Alert |
02/23/2024 | Buy Now | 27.26% | Baird | Colleen Kusy | → $105 | Initiates | → Outperform | Get Alert |
10/19/2023 | Buy Now | -4.25% | BMO Capital | Etzer Darout | $73 → $79 | Maintains | Outperform | Get Alert |
10/05/2023 | Buy Now | -17.59% | JP Morgan | Anupam Rama | $51 → $68 | Maintains | Overweight | Get Alert |
10/05/2023 | Buy Now | -11.53% | BMO Capital | Etzer Darout | $52 → $73 | Maintains | Outperform | Get Alert |
10/04/2023 | Buy Now | — | Stifel | Bradley Canino | — | Reiterates | → Buy | Get Alert |
09/27/2023 | Buy Now | -21.22% | Stifel | Bradley Canino | → $65 | Initiates | → Buy | Get Alert |
08/08/2023 | Buy Now | -49.1% | SVB Leerink | Christopher Liu | → $42 | Initiates | → Market Perform | Get Alert |
07/24/2023 | Buy Now | -32.13% | Guggenheim | Charles Zhu | → $56 | Initiates | → Buy | Get Alert |
07/20/2023 | Buy Now | -35.77% | Wedbush | David Nierengarten | → $53 | Reiterates | Outperform → Outperform | Get Alert |
06/23/2023 | Buy Now | -41.83% | JP Morgan | Anupam Rama | $37 → $48 | Maintains | Overweight | Get Alert |
01/18/2023 | Buy Now | -52.73% | Wedbush | David Nierengarten | → $39 | Initiates | → Outperform | Get Alert |
06/24/2022 | Buy Now | -66.06% | BMO Capital | Etzer Darout | → $28 | Initiates | → Outperform | Get Alert |
08/23/2021 | Buy Now | — | Cowen & Co. | Marc Frahm | — | Initiates | → Outperform | Get Alert |
08/23/2021 | Buy Now | -58.79% | JP Morgan | Anupam Rama | — | Initiates | → Overweight | Get Alert |
08/23/2021 | Buy Now | -51.52% | Piper Sandler | Christopher Raymond | — | Initiates | → Overweight | Get Alert |
The latest price target for Nuvalent (NASDAQ:NUVL) was reported by Stifel on July 10, 2024. The analyst firm set a price target for $115.00 expecting NUVL to rise to within 12 months (a possible 39.38% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for Nuvalent (NASDAQ:NUVL) was provided by Stifel, and Nuvalent maintained their buy rating.
The last upgrade for Nuvalent Inc happened on April 1, 2024 when Leerink Partners raised their price target to $110. Leerink Partners previously had a market perform for Nuvalent Inc.
There is no last downgrade for Nuvalent.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvalent, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvalent was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
While ratings are subjective and will change, the latest Nuvalent (NUVL) rating was a maintained with a price target of $103.00 to $115.00. The current price Nuvalent (NUVL) is trading at is $82.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.